What ENPICOM does

ENPICOM B.V. is a Netherlands-based bioinformatics software company founded in 2015 and headquartered in 's-Hertogenbosch. The company builds the ENPICOM Platform, a SaaS-based discovery operating system designed specifically for biologics — primarily antibody and immune-repertoire discovery workflows used by pharmaceutical and biotechnology companies. The platform processes NGS, Sanger, and single-cell sequencing data at scale, delivering end-to-end pipelines for in vitro and in vivo antibody lead selection, including clone annotation, quality control, clonotype clustering, enrichment analysis, developability analysis, and candidate prioritization.

The technology stack is biologics-specific rather than generic lab automation, with integrated modules covering pipeline automation, an AI Agent interface (exposed via the Model Context Protocol), ML model integration, and system integration with existing LIMS, ELNs, data lakes, and CRO deliverables. ENPICOM holds ISO 27001 certification and deploys engineering teams alongside client scientists to scope and build tailored pipelines, typically live within 4-8 weeks. The company also produces the 'Models & Molecules' podcast as a content and thought-leadership channel.

ENPICOM operates a direct enterprise sales motion with quote-based annual subscriptions and bundled professional services for pipeline deployment. The customer base spans top-10 pharmaceutical companies, biotech firms, academic institutions, and a network of 27+ partner organizations including Illumina, Carterra, LifeArc, NGM Bio, and Erasmus MC. Total disclosed equity funding is approximately $1.36 million across two rounds (2015 and 2019), with investors including Arches Capital, BOM Brabant Ventures, NextGen Ventures, and ACE Incubator. The leadership team is led by founder and CEO Nicola Bonzanni, with Jorrit Posthuma as CTO, Pim Fuchs as CAIO, Pablo Mendes de León as CFO & COO, and Ron van Eijsden as CBO.

Name

ENPICOM

Legal name

ENPICOM B.V.

Website

https://enpicom.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

ENPICOM B.V. is a Netherlands-based bioinformatics software company (founded 2015) that provides a SaaS discovery operating system for antibody and immune-repertoire workflows, serving top-10 pharma, biotech, and academic customers with integrated pipeline automation, ML, and AI-agent capabilities.

Ownership category

akta.pro rank

Product category

Bioinformatics Software for Antibody & Biologics Discovery

NAICS

Software Publishers (513210), Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Bioinformatics software
• Antibody discovery
• Biologics analytics
• Immune repertoire analysis
• Sequencing data platform

Headquarters

HQ city

's-hertogenbosch

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. SaaS Platform Subscription: ENPICOM provides its discovery platform as a SaaS product. Customers pay subscription fees for access to the platform, with pipeline deployment and engineering support included as part of the engagement. Terms indicate automatic annual renewal unless terminated two months before expiry.
2. Professional Services (Pipeline Deployment): ENPICOM deploys a team of engineers alongside client scientists to scope, build, and deploy tailored discovery pipelines within 4-8 weeks. This engineering deployment is a core component of the commercial engagement model.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ENPICOM provides a SaaS-based discovery operating system that ingests sequencing data and applies AI- and ML-driven analytics for antibody and biologics discovery. The platform supports in vitro and in vivo discovery workflows, automates end-to-end pipelines, and exposes an MCP-based Agent Interface so AI agents can interact with discovery data. The offering is targeted at pharma, biotech, and academic researchers developing therapeutic antibodies and other biologics.

Product overview

ENPICOM offers a unified platform-plus-modules architecture centered on the ENPICOM Platform — a discovery operating system for biologics. The core platform provides end-to-end analysis-workflow orchestration for immune-repertoire and antibody sequence analysis, processing billions of sequences in hours. The product portfolio comprises two primary solution modules — In vitro Antibody Discovery and In vivo Antibody Discovery — which cover clone annotation, quality control, clonotype clustering, enrichment analysis, developability analysis, and candidate prioritization. Supporting capability modules include Pipeline Automation, Agent Interface, AI Adoption (ML model integration), and System Integration. ENPICOM also produces the Models & Molecules Podcast as a content/marketing sub-brand. Note: An older IGX Platform is referenced in historical terms and conditions but appears superseded by the current ENPICOM Platform.

Differentiator

Problem solved

Functional benefit

Brands

• ENPICOM Platform: The operating system for biologics discovery - a software platform providing end-to-end environment for analysis-workflow orchestration covering immune-repertoire and antibody sequence analysis, data integration, assay and screening management, and developability tracking.
• Models & Molecules Podcast

Quantifiable outcome

• 4× faster pipeline deployment — pipelines live in 4-8 weeks, not a 12-month implementation project
• +7 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature8 records

Partnerships

27 partnerships are on record, tiered core.

• IlluminacoreTechnology or IntegrationIllumina is listed as a partner logo on ENPICOM's website, indicating a technology integration or collaboration. Illumina provides next-generation sequencing (NGS) platforms that are a core data source for ENPICOM's discovery pipelines. ENPICOM connects to sequencing platforms including Illumina as part of its end-to-end pipeline automation.
• CarterracoreTechnology or IntegrationCarterra is listed as a partner logo. Carterra provides high-throughput antibody screening and characterization platforms. The partnership integrates Carterra's experimental data with ENPICOM's analytical pipelines.
• LifeArccoreStrategic or Co-development PartnerLifeArc is listed as a partner logo. LifeArc is a UK-based medical research charity engaged in translational biomedical research and drug discovery, indicating a co-development or strategic collaboration in antibody discovery.
• Erasmus MCcoreStrategic or Co-development PartnerErasmus MC (Erasmus University Medical Center Rotterdam) is listed as a partner logo, representing a strategic collaboration with a leading academic medical center for biologics and immunology research.
• University of OxfordcoreStrategic or Co-development PartnerUniversity of Oxford is listed as a partner logo. The collaboration connects ENPICOM's discovery platform with Oxford's academic research capabilities in antibody discovery and immunology.
• Weizmann InstitutecoreStrategic or Co-development PartnerWeizmann Institute of Science is listed as a partner logo. The collaboration provides access to cutting-edge immunology research capabilities for biologics discovery.
• UCL (University College London)coreStrategic or Co-development PartnerUCL is listed as a partner logo, representing a collaboration with one of the UK's leading research universities for biologics and computational biology research.
• Radboud UniversitycoreStrategic or Co-development PartnerRadboud University (Nijmegen, Netherlands) is listed as a partner logo, indicating a collaboration in academic biologics and immunology research.
• Ghent UniversitycoreStrategic or Co-development PartnerGhent University (Universiteit Gent) is listed as a partner logo, representing a research collaboration in biologics discovery.
• VU AmsterdamcoreStrategic or Co-development PartnerVU Amsterdam is listed as a partner logo, indicating a research collaboration with one of Amsterdam's major universities in the field of immunology and biologics.
• Utrecht UniversitycoreStrategic or Co-development PartnerUtrecht University is listed as a partner logo, representing a collaboration with a leading Dutch research university in antibody and biologics research.
• Aalborg UniversitycoreStrategic or Co-development PartnerAalborg University (Denmark) is listed as a partner logo, indicating a research collaboration in computational biology and biologics discovery.
• TUM (Technical University of Munich)coreStrategic or Co-development PartnerTUM is listed as a partner logo, representing a collaboration with a leading German technical university in computational life sciences and biologics research.
• KGI (Keck Graduate Institute)coreStrategic or Co-development PartnerKGI is listed as a partner logo. Keck Graduate Institute in Claremont, CA specializes in applied life sciences and biotech, indicating a collaboration in biologics education and/or research.
• University of MichigancoreStrategic or Co-development PartnerUniversity of Michigan is listed as a partner logo, representing a collaboration with a leading US research university in computational biology and antibody discovery.
• Queen Mary University of LondoncoreStrategic or Co-development PartnerQueen Mary University of London is listed as a partner logo, indicating a research collaboration in biologics and immunology.
• Inno4vaccoreStrategic or Co-development PartnerInno4vac is listed as a partner logo. Inno4vac is focused on innovation in vaccine and immunotherapy development, suggesting a collaborative effort in biologics discovery methodologies.
• MabyloncoreStrategic or Co-development PartnerMabylon is listed as a partner logo, representing a collaboration with a biotech company engaged in antibody discovery and development.
• Memo TherapeuticscoreStrategic or Co-development PartnerMemo Therapeutics is listed as a partner logo, indicating a collaborative relationship with a biotech company specializing in antibody discovery.
• Kling BiotherapeuticscoreStrategic or Co-development PartnerKling Biotherapeutics is listed as a partner logo, representing a collaboration with a biotherapeutics company engaged in antibody discovery.
• GenovaccoreStrategic or Co-development PartnerGenovac is listed as a partner logo, indicating a collaboration with an antibody discovery and development biotech company.
• NGM BiocoreStrategic or Co-development PartnerNGM Bio is listed as a partner logo. NGM Therapeutics is a biopharmaceutical company focused on discovering and developing novel biologics, indicating a collaborative discovery relationship.
• Aethon TherapeuticscoreStrategic or Co-development PartnerAethon Therapeutics is listed as a partner logo, representing a collaboration with a biotherapeutics company engaged in antibody and drug discovery.
• AdAltacoreStrategic or Co-development PartnerAdAlta is listed as a partner logo. AdAlta is an Australian biotech company developing antibody therapeutics using its i-body platform.
• Cerba ResearchcoreStrategic or Co-development PartnerCerba Research is listed as a partner logo, representing a collaboration with a CRO specializing in preclinical and clinical research services for biologics.
• RxBiologicscoreStrategic or Co-development PartnerRxBiologics is listed as a partner logo, indicating a collaboration with a biopharmaceutical company engaged in biologics development.
• Neogene TherapeuticscoreStrategic or Co-development PartnerNeogene Therapeutics is listed as a partner logo. Neogene is focused on T-cell receptor (TCR) engineered T-cell therapies, suggesting collaboration in novel biologics discovery.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Schrödinger: Schrödinger operates a much broader computational chemistry, biology, and materials science platform with enterprise pharma customers. It is comparable as a higher-level incumbent offering predictive modeling and discovery software that overlaps with ENPICOM's AI-enabled biologics discovery workflow.
• Veeva Systems: Veeva provides cloud software for life sciences, including R&D, quality, regulatory, and commercial domains used by most large pharma companies. It is a broad incumbent whose R&D cloud product competes for the same enterprise life sciences IT wallet that ENPICOM addresses.

Direct peers

• TetraScience: TetraScience operates a life sciences R&D data cloud that harmonizes instrument and experimental data for pharma customers, similar in architecture and enterprise pharma focus to ENPICOM. Both compete to be the connective tissue between wet lab data sources and analytical/AI workflows.
• Dotmatics: Dotmatics delivers a scientific informatics platform (LIMS, ELN, data management, analytics) widely used by pharma and biotech R&D organizations. It overlaps with ENPICOM's offering in laboratory data integration and discovery analytics for biologics programs.
• Genedata: Genedata provides enterprise bioinformatics and R&D informatics solutions for pharma, industrial biotech, and diagnostics, including specialized biologics screening and characterization workflows. It is directly comparable to ENPICOM's enterprise biologics bioinformatics positioning and long-running pharma customer footprint.
• DNAnexus: DNAnexus provides a cloud-based biomedical data analysis and management platform used by pharma, biotech, and clinical labs for genomics and multi-omics workflows. It is directly comparable to ENPICOM as a bioinformatics SaaS serving enterprise life sciences customers with similar data integration and pipeline orchestration capabilities.
• IDBS: IDBS provides ELN, LIMS, and bioprocess informatics used by global biopharma R&D and manufacturing organizations. It is comparable to ENPICOM as an enterprise life sciences data management and workflow platform with deep pharma penetration.
• Benchling: Benchling offers a cloud R&D platform spanning ELN, LIMS, registration, and molecular biology workflows used by leading pharma and biotech companies. It is directly comparable because it competes for the same enterprise R&D informatics budget and increasingly covers biologics and antibody engineering use cases that ENPICOM targets.

Emerging players

• AbCellera Biologics: AbCellera is a clinical-stage biotech that combines a proprietary antibody discovery platform with AI/ML capabilities to identify lead candidates for partners. It is comparable to ENPICOM as a technology-forward antibody discovery player, though AbCellera integrates wet-lab capabilities ENPICOM does not own.
• Specifica (an Astellas company): Specifica developed antibody discovery libraries and analytics tooling for therapeutic antibody generation, focusing on in vitro display-based discovery. It is comparable to ENPICOM as a niche antibody discovery technology platform with overlapping customer base among biotech and pharma R&D teams.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC1T2PKGic7LxWzO5SnYebwg
• Xx.com/enpicom

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENPICOM